Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Prelude Therapeutics Inc stock

Learn how to easily invest in Prelude Therapeutics Inc stock.

Prelude Therapeutics Inc is a biotechnology business based in the US. Prelude Therapeutics Inc shares (PRLD) are listed on the NASDAQ and all prices are listed in US Dollars. Prelude Therapeutics Inc employs 120 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Prelude Therapeutics Inc stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – PRLD. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Prelude Therapeutics Inc stock price (NASDAQ: PRLD)

Use our graph to track the performance of PRLD stocks over time.

Prelude Therapeutics Inc shares at a glance

Information last updated 2023-01-26.
Latest market close$6.07
52-week range$3.87 - $10.72
50-day moving average $6.02
200-day moving average $6.05
Wall St. target price$9.60
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.58

Buy Prelude Therapeutics Inc stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Prelude Therapeutics Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Prelude Therapeutics Inc price performance over time

Historical closes compared with the close of $6.07 from 2023-01-30

1 week (2023-01-25) -17.30%
1 month (2022-12-30) 0.50%
3 months (2022-11-01) -8.72%
6 months (2022-08-01) 20.20%
1 year (2022-01-28) -37.29%
2 years (2021-02-01) -91.26%
3 years (2020-01-28) N/A
5 years (2018-01-28) N/A

Prelude Therapeutics Inc financials

Gross profit TTM $0
Return on assets TTM -26.84%
Return on equity TTM -45.26%
Profit margin 0%
Book value $4.57
Market capitalisation $347.8 million

TTM: trailing 12 months

Prelude Therapeutics Inc share dividends

We're not expecting Prelude Therapeutics Inc to pay a dividend over the next 12 months.

Prelude Therapeutics Inc share price volatility

Over the last 12 months, Prelude Therapeutics Inc's shares have ranged in value from as little as $3.87 up to $10.72. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Prelude Therapeutics Inc's is 0.3706. This would suggest that Prelude Therapeutics Inc's shares are less volatile than average (for this exchange).

To put Prelude Therapeutics Inc's beta into context you can compare it against those of similar companies.

Prelude Therapeutics Inc overview

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. .

Frequently asked questions

What percentage of Prelude Therapeutics Inc is owned by insiders or institutions?
Currently 7.399% of Prelude Therapeutics Inc shares are held by insiders and 78.631% by institutions.
How many people work for Prelude Therapeutics Inc?
Latest data suggests 120 work at Prelude Therapeutics Inc.
When does the fiscal year end for Prelude Therapeutics Inc?
Prelude Therapeutics Inc's fiscal year ends in December.
Where is Prelude Therapeutics Inc based?
Prelude Therapeutics Inc's address is: 200 Powder Mill Road, Wilmington, DE, United States, 19803
What is Prelude Therapeutics Inc's ISIN number?
Prelude Therapeutics Inc's international securities identification number is: US74065P1012

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site